Online citations, reference lists, and bibliographies.

A Validated LC-MS/MS Method For The Estimation Of Apixaban In Human Plasma. -

Mirza Layeeq Ahmed Baig, Syed Ayaz Ali
Published 2017 · Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
A high performance liquid chromatography mass spectrometric method for the estimation of apixaban in human plasma has been developed and validated using apixaban 13CD3 as an internal standard (IS). The extraction of analyte and IS was accomplished by liquid-liquid extraction technique. The method has been validated over a concentration range of 1.00 ng mL-1 to 301.52 ng mL-1. Chromatographic separations was achieved using Thermo Beta basic-8, 100 mm x 4.6 mm, 5μ, column eluted at flow rate of 1.0 mL minute-1 with 1:1 splitted post column with mobile phase Acetonitrile: Ammonium formate buffer pH 4.2 (70:30 v/v).The overall run time of method was about 3.0 min. with elution times of apixaban and its internal standard apixaban 13CD3 at around 1.2 min. The multiple reaction monitoring transitions were set at 460.2 > 443.2 (m/z) and 464.2>447.4 (m/z) for apixaban and apixaban 13CD3 respectively. The calibration curves were linear (r2≥0.99) over the range of 1.0-301.52 ng mL-1 with lower limit of quantitation validated at 1.0 ng mL-1. Extraction recoveries were >98 % for both apixaban and its stable labeled IS apixaban 13CD3. The within run and between run precisions were within 0.70%-6.98%, while accuracy ranged from 89.2 to 107.2%.
This paper references
apixaban Pharmacokinetics and Pharmacodynamics in Subjects With Renal Impairment : 1381212
Ming Che Chang (2012)
10.1160/TH10-05-0328
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Y. C. Barrett (2010)
10.1007/s11239-016-1367-y
Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC–MS/MS method
Wanli Zhang (2016)
In vitro assessment
Baig (2017)
10.1016/S0002-9343(02)01131-2
Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial.
D. Matchar (2002)
10.2165/11595320-000000000-00000
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
W. Mueck (2011)
10.1124/dmd.109.029694
In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies
L. Wang (2010)
10.1515/cclm-2014-1108
Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry
Cornelia Blaich (2015)
10.1097/FTD.0000000000000059
Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry
Tracey Gous (2014)
10.1186/1477-9560-11-10
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring
W. Mueck (2013)
GLUCURONIDATION AS A MAJOR METABOLIC CLEARANCE PATHWAY OF 14 C-LABELED MURAGLITAZAR IN HUMANS : METABOLIC PROFILES IN SUBJECTS WITH OR WITHOUT
L. Wang (2006)
10.7324/japs.2017.70406
A Validated LC-MS/MS Method for the Estimation of Apixaban in Human Plasma. -
Mirza Layeeq Ahmed Baig (2017)
10.1007/978-1-4939-3252-8_3
Quantitation of the Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Plasma Using Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS).
Jaime H. Noguez (2016)
10.1016/j.jpba.2013.02.007
Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study.
X. Delavenne (2013)
10.4155/bio.15.261
Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma.
S. Baldelli (2016)
10.1111/j.1538-7836.2004.00659.x
Patient self‐management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life
A. P. A. Gadisseur (2004)
10.1111/jth.12702
Determination of dabigatran, rivaroxaban and apixaban by ultra‐performance liquid chromatography – tandem mass spectrometry (UPLC‐MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants
E. M. H. Schmitz (2014)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar